DCPH - Deciphera up to 6% up EC approval of gastrointestinal stromal tumor drug

Shares of Deciphera Pharmaceuticals are (NASDAQ:DCPH) up 6% after the European Commission approved Qinlock (ripretinib) as a fourth-line treatment for gastrointestinal stromal tumors. A pivotal trial showed that the drug increased overall survival compared to best supportive care. It also maintained quality of life. In the INVICTUS study, Qinlock demonstrated a median progression-free survival of 6.3 months compared to one month for placebo. It also significantly reduced the risk of disease progression or death by 85%. Read about recent results for another phase 3 trial of Qinlock.

For further details see:

Deciphera up to 6% up EC approval of gastrointestinal stromal tumor drug